Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

He Ren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9528-0580; OpenAlex author ID A5071436467, A5123177150. Sources: OpenAlex.

Their work

Papers
36 (first author 4, last author 17)
Trials
0
Grants
0
Labs led
2
Collaborators
67
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 5 papers · 2015: 3 papers · 2016: 4 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: none · 2024: 4 papers · 2025: 4 papers · 2026: 3 papers

Papers 36

  1. EGFR-Targeting IgG1 Antibody Enhances NK Cell-Mediated Tumor Killing in KRAS-Mutant Pancreatic Cancer. Last author DOI 10.1002/mco2.70860↗
  2. Cancer cell-specific FOXP3 licenses MMP19-dependent matrix remodeling and metastatic dissemination in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41388-026-04025-y↗
  3. Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory facto… Last author DOI 10.1038/s41392-025-02562-8↗
  4. hnRNPLL regulates MYOF alternative splicing and correlates with early metastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2024.217436↗
  5. Design of nano-delivery systems for pancreatic cancer immunotherapy. Last author DOI 10.1016/j.canlet.2025.218098↗
  6. Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancreatic Cancer: A Multicenter Study. Last author DOI 10.1158/1078-0432.ccr-24-4300↗
  7. HCST Expression Distinguishes Immune-hot and Immune-cold Subtypes in Pancreatic Ductal Adenocarcinoma Last author DOI 10.2174/1566523223666230720101531↗
  8. Precision treatment of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2024.216636↗
  9. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma. Last author DOI 10.1016/j.canlet.2024.216838↗
  10. Hepatic Macrophage Migration Inhibitory Factor Promotes Pancreatic Cancer Liver Metastasis in NAFLD Last author DOI 10.1101/2024.06.02.595997↗
  11. hnRNPAB Promotes Pancreatic Ductal Adenocarcinoma Extravasation and Liver Metastasis by Stabilizing MYC mRNA. Last author DOI 10.1158/1541-7786.mcr-24-0110↗
  12. GPR120 promotes metastasis but inhibits tumor growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.06.006↗
  13. Injectable Immunotherapeutic Hydrogel Containing RNA-Loaded Lipid Nanoparticles Reshapes Tumor Microenvironment for Pancreatic Cancer Therapy. Last author DOI 10.1021/acs.nanolett.2c01994↗
  14. Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.02.016↗
  15. VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo. Co-author DOI 10.20892/j.issn.2095-3941.2020.0568↗
  16. Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectable pancreatic cancer. Last author DOI 10.2217/pgs-2020-0183↗
  17. Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41392-020-00267-8↗
  18. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effec… Last author DOI 10.1038/s41392-020-0144-8↗
  19. LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation. Last author DOI 10.1158/1078-0432.ccr-18-3533↗
  20. Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. Last author DOI 10.1016/j.biomaterials.2017.12.015↗
  21. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/onc.2016.458↗
  22. Berries and other natural products in the pancreatic cancer chemoprevention in human clinical trials. Co-author DOI 10.3233/jbr-170159↗
  23. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Co-author DOI 10.1016/j.biomaterials.2016.06.032↗
  24. Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis. Co-author DOI 10.1016/j.molonc.2016.07.001↗
  25. IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-16-0438↗
  26. Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms17060799↗
  27. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2014.12.028↗
  28. LASP1 is a HIF1α target gene critical for metastasis of pancreatic cancer. First author DOI 10.1158/0008-5472.can-14-2040↗
  29. SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. Co-author DOI 10.1371/journal.pone.0121338↗
  30. Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Co-author DOI 10.1007/s12032-014-0857-z↗
  31. Hypoxia inducible factor (HIF)-1α directly activates leptin receptor (Ob-R) in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2014.08.001↗
  32. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. First author DOI 10.1016/j.humimm.2013.09.018↗
  33. Resection or cryosurgery relates with pancreatic tumor type: primary pancreatic cancer with previous non-pancreatic cancer or secondary metastatic cancer withi… Co-author DOI 10.1016/j.pan.2013.11.001↗
  34. Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Co-author DOI 10.1158/0008-5472.can-13-3009↗
  35. The CX3CL1/CX3CR1 reprograms glucose metabolism through HIF-1 pathway in pancreatic adenocarcinoma. Co-author DOI 10.1002/jcb.24608↗
  36. Polymorphisms in the hypoxia-inducible factor-1α gene confer susceptibility to pancreatic cancer. Co-author DOI 10.4161/cbt.12.5.15982↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ruining Gong · 11 shared papers, 2020–2026 · strength 2.49
  2. Ke Lei · 6 shared papers, 2022–2026 · strength 1.34
  3. Qian Yu · 5 shared papers, 2024–2026 · strength 1.09
  4. Jihui Hao · 18 shared papers, 2011–2021 · strength 1.03
  5. Xianghan Chen · 4 shared papers, 2024–2025 · strength 0.90
  6. Xiuchao Wang · 11 shared papers, 2011–2026 · strength 0.87
  7. Chao Gao · 3 shared papers, 2022–2026 · strength 0.60
  8. Jigang Wang · 3 shared papers, 2024–2025 · strength 0.60
  9. Junjin Wang · 2 shared papers, 2026 · strength 0.59
  10. Ashok Kumar Saluja · 3 shared papers, 2024–2026 · strength 0.59
  11. Tiansuo Zhao · 8 shared papers, 2011–2025 · strength 0.58
  12. Hongyun Wei · 1 shared paper, 2024 · strength 0.46
  13. Xiaoya Shi · 2 shared papers, 2025–2026 · strength 0.44
  14. Guangjun Nie · 4 shared papers, 2015–2022 · strength 0.34
  15. Huan Zhang · 4 shared papers, 2014–2026 · strength 0.32
  16. Song Gao · 5 shared papers, 2013–2021 · strength 0.30
  17. Shengyu Yang · 4 shared papers, 2014–2020 · strength 0.28
  18. Ruoxi Xiao · 1 shared paper, 2026 · strength 0.28
  19. Boyi Ma · 1 shared paper, 2025 · strength 0.27
  20. Xiao Ling Zhao · 5 shared papers, 2014–2018 · strength 0.26
  21. Feng Wei · 1 shared paper, 2025 · strength 0.26
  22. Lianjing Cao · 1 shared paper, 2025 · strength 0.26
  23. Xin Li · 2 shared papers, 2020–2021 · strength 0.25
  24. Shunli Fu · 1 shared paper, 2025 · strength 0.24
  25. Zhan Yang · 1 shared paper, 2025 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.